Abstract
The SARS-CoV-2 pandemic triggered substantial economic and social disruptions. Mitigation policies varied across countries based on resources, political conditions, and human behavior. In the absence of widespread vaccination able to induce herd immunity, strategies to coexist with the virus while minimizing risks of surges are paramount, which should work in parallel with reopening societies. To support these strategies, we present a predictive control system coupled with a nonlinear model able to optimize the level of policies to stop epidemic growth. We applied this system to study the unfolding of COVID-19 in Bahia, Brazil, also assessing the effects of varying population compliance. We show the importance of finely tuning the levels of enforced measures to achieve SARS-CoV-2 containment, with periodic interventions emerging as an optimal control strategy in the long-term.
One-sentence summary We present an adaptive predictive control algorithm to provide optimal public health measures to slow the COVID-19 transmission rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
IMLP was supported by CNPq (process number 201143/2019-4). JFO was supported by the Center of Data and Knowledge Integration for Health (CIDACS) through the Zika Platform, a long-term surveillance platform for Zika virus and microcephaly (Unified Health System (SUS), Brazilian Ministry of Health. CIDACS is recipient of a Biomedical Resource Grant from Wellcome Trust, UK). AASA gratefully acknowledges the financial support received from the Engineering and Physical Sciences Research Council (EPSRC) in the form of grant EP/R002134/1. RFSA was supported by the National Institute of Science and Technology-Complex Systems from CNPq, Brazil. MSS was supported by CNPq (process number 117790/2020-6). DCJ acknowledges a Scientfiic Initiation scholarship from CNPq (process number 117568/2019-8).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted with anonymized secondary data, where only aggregated clinical data was used for model parameterization. Therefore, no approval from a Human Research Ethics Committee is required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are openly available in the repository of Center for Data and Knowledge Integration for Health (CIDACS) at https://github.com/cidacslab/covid-control-policies.
